Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | SLC2A9 | Q9NRM0 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5366940 | 1.00 | DPP4 (0.49) | DPP4DPP7KCNH2DPP8DPP9 | |
| SCHEMBL6598747 | 0.91 | HTR1A (0.44) | DPP4DPP7KCNH2DPP8DPP9 | |
| SCHEMBL5355687 | 0.86 | HSD17B1 (0.41) | DPP4DPP7KCNH2DPP8DPP9 | |
| SCHEMBL5355689 | 0.86 | HSD17B1 (0.41) | DPP4DPP7KCNH2DPP8DPP9 | |
| SCHEMBL5356341 | 0.84 | KMT2A (0.48) | KMT2ATDP1 | |
| SCHEMBL5356347 | 0.84 | KMT2A (0.48) | KMT2ATDP1 | |
| SCHEMBL6599031 | 0.84 | KMT2A (0.48) | KMT2ATDP1 | |
| SCHEMBL5359472 | 0.81 | KMT2A (0.40) | KMT2ATDP1 | |
| SCHEMBL5359477 | 0.81 | KMT2A (0.40) | KMT2ATDP1 | |
| SCHEMBL5363002 | 0.77 | KMT2A (0.52) | HDAC8KMT2ATDP1GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852747-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-02-08 | — | — | US | claimed |
| EP-1317425-B1 | RESORCINOL DERIVATIVES | PFIZER PROD INC (US) | 2004-11-03 | — | — | EP | claimed |
| US-20030180236-A1 | Resorcinol derivatives | PFIZER PRODUCTS, INC. | 2003-09-25 | — | — | US | claimed |
| EP-1317425-A2 | RESORCINOL DERIVATIVES | Pfizer Products Inc. (US) | 2003-06-11 | — | — | EP | claimed |
| US-20020114770-A1 | Resorcinol derivatives | PFIZER INC. | 2002-08-22 | — | — | US | claimed |
| WO-2002020474-A2 | RESORCINOL DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-03-14 | — | — | WO | claimed |
| US-7282592-B2 | Resorcinol derivatives | WARNER-LAMBERT COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070122367-A1 | RESORCINOL DERIVATIVES | PFIZER INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-7173052-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050282899-A1 | Resorcinol for lightening skin removing color | BRADLEY STUART E | 2005-12-22 | — | — | US | disclosed |
| US-6852747-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1317425-B1 | RESORCINOL DERIVATIVES | PFIZER PROD INC (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20030180236-A1 | Resorcinol derivatives | PFIZER PRODUCTS, INC. | 2003-09-25 | — | — | US | disclosed |
| US-6590105-B2 | For skin lightening or depigmentation; works by inhibiting tyrosinase in humans; kits | WARNER-LAMBERT COMPANY | 2003-07-08 | — | — | US | disclosed |
| US-20020114770-A1 | Resorcinol derivatives | PFIZER INC. | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070122367-A1 | RESORCINOL DERIVATIVES | LRAT, NQO1, ALDH1A2 | DPP4 1407/4885DPP7 2744/4885KCNH2 3280/4885 |
| US-20030180236-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | DPP4 1407/4885DPP7 2744/4885KCNH2 3280/4885 |
| US-20050282899-A1 | Resorcinol for lightening skin removing color | RBP4, NQO1, ALDH1A2 | DPP4 639/4885DPP7 2203/4885KCNH2 2960/4885 |
| US-20020114770-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | DPP4 1407/4885DPP7 2744/4885KCNH2 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.